Log In
Print
BCIQ
Print
Print this Print this
 

DX-2930

  Manage Alerts
Collapse Summary General Information
Company Dyax Corp.
DescriptionHuman mAb against plasma kallikrein
Molecular Target Kallikrein
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAngioedema
Indication DetailsPrevent hereditary angioedema (HAE) attacks; Treat and prevent hereditary angioedema (HAE) attacks; Treat hereditary angioedema (HAE)
Regulatory Designation

U.S. - Orphan Drug (Treat hereditary angioedema (HAE))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today